• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/13

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

13 Cards in this Set

  • Front
  • Back

What are the 4 As of dementia?


  • Amnesia
  • Aphasia
  • Apraxia
  • Agnosia

Criteria A for major neurocognitive disorder?

evidence of significant cognitive decline from a previous level of performance in one or morecognitive domains (complex attention, executive function, learning and memory, language,perceptual-motor, or social cognition) based on concern of the individual, a knowledgeable informant, or the clinician that there has beena significant decline in cognitive function;and a substantial impairment in cognitive performance, preferably documented bystandardized neuropsychological testing or, in its absence, another quantified clinicalassessment

Criteria B for major neurocognitive disorder?

the cognitive deficits interfere with independence in everyday activities (i.e. at a minimum,requiring assistance with complex instrumental activities of daily living such as paying bills ormanaging medications)

Criteria C and D for major neurocognitive disorder?


  • the cognitive deficits do not occur exclusively in
  • the context of a delirium the cognitive deficits are not better explained by another mental disorder (e.g. major depressive disorder, schizophrenia)

What are the most common types of dementia? (4)

• Alzheimer’s dementia > 50% of cases


• Vascular dementia 15% of cases


• Lewy body dementia


• Fronto-temporal dementia

When diagnosing major neurocognitive disorder, what must you specify it is due to?


  • Either
  • Alxheimer's disease
  • Frontotemporal lobar degeneration
  • Lewy body disease
  • Vascular disease
  • TBI
  • Substance use/meds
  • HIV infection
  • Prion disease
  • Parkinson's disease
  • Huntington's
  • another med condition
  • multiple etiologies
  • unspecified

T/F: major neurocognitive disorder prevalence increases with age?

True: 10% in patients >65 yr of age; 25% in patients >85 yr of age

How does down syndrome/head trauma impact prevalence of major neurocognitive disorder?

prevalence increases

Average duration of illness?

Average duration of onset of symptoms to death is 8-10 years

Substypes of major neurocognitive disorder?

• with or without behavioral disturbance (e.g. wandering, agitation)


• early onset: age of onset <65 yr


• late onset: age of onset >65 yr

What investigations to rule out reversible causes when diagnosing major neurocognitive disorder?


  • standard: same as delirium
  • as indicated: VDRL, HIV, SPECT, CT head in dementia
  • indications for CT head: same as for delirium, plus: age <60, rapid onset (unexplained declinein cognition or function over 1-2 mo), dementia of relatively short duration (<2 yr), recentsignificant head trauma, unexplained neurological symptoms (new onset of severe headache/seizures)

How to manage major neurocognitive disorder

• treat underlying medical problems and prevent others


• provide orientation cues for patient (e.g. clock, calendar)


• provide education and support for patient and family (e.g. day programs, respite care, support groups, home care)


• consider long-term care plan (nursing home) and power of attorney/living will


• inform Ministry of Transportation about patient’s inability to drive safely


• consider pharmacological therapy

Pharmacological therapy in major neurocognitive disorder?


  • cholinesterase inhibitors (e.g. donepezil [Aricept®]) for mild to severe disease
  • NMDA receptor antagonist (e.g. memantine) for moderate to severe disease
  • low-dose neuroleptics (e.g. risperidone, quetiapine), antidepressants or trazodone if behavioral or emotional symptoms prominent – start low and go slow
  • reassess pharmacological therapy every 3 mo